• Sitemap
  • Contact Us

pISSN 2950-9114 eISSN 2950-9122
Article View

Report On Proficiency Testing

Lab Med Qual Assur 2024; 46(2): 73-77

Published online June 30, 2024


Copyright © Korean Association of External Quality Assessment Service.

Annual Report of the Korean External Quality Assessment Service on General Transfusion Medicine and General Transfusion Antibody Tests (2023)

Han Joo Kim1 , Jin Seok Kim1 , Suk-Won Seo1 , Hyungsuk Kim2 , Duck Cho3 , and Dae-Hyun Ko1

1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine; 2Department of Laboratory Medicine, Seoul National University Hospital; 3Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to:Dae-Hyun Ko
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel +82-2-3010-4504
E-mail daehyuni1118@amc.seoul.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


This report aimed to provide a summary of the 2023 survey results on the external quality assessment (EQA) scheme for the general transfusion medicine test and general transfusion antibody test programs in Korea. Proficiency testing materials were prepared at the Asan Medical Center for biannual distribution to participating laboratories. The accuracy rates and number of participating laboratories were as follows: ABO typing, 99.8%–100.0% (n=940, n=940); RhD typing, 99.8%–100.0% (n=924, n=918); crossmatching, 95.6%–99.4% (n=802, n=825); unexpected antibody screening, 99.4–100.0% (n=358, n=358); direct antiglobulin test (DAT) using a polyspecific reagent, 99.3%–100.0% (n=296, n=292); DAT using anti-immunoglobulin G monospecific reagent, 100.0% (n=76, n=76); and DAT using anti-C3d monospecific reagent, 97.3%–100.0% (n=73, n=73). The 2023 EQA scheme for transfusion medicine program has improved and maintained the standards of the participating laboratories.

Keywords: Transfusion medicine, Quality improvement, Laboratory proficiency testing

Supplementary File

Share this article on :

Stats or metrics